1.Yamashita T,Sohn JH,Tokunaga E,et al.Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer:subgroup analysis of the DESTINY-Breast04 study.Breast Cancer.2024;31(5):858-868.doi:10.1007/s12282-024-01...
NCCN: Breast cancerCarlson RW; Edge SB; Theriault RL; NCCN Breast Cancer Practice Guidelines PanelCancer ControlCancer control : journal of the Moffitt Cancer Center
William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing unmet needs at ASCO 2024. This is a modal window. The Playback API request failed for an ...
Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis Risk Stratification and Treatment Selection in HER2+ Breast Cancer: The Current Treatment Landscape and NCCN Guideline Recommendations Future of TROP2- and HER2-Directed ADCs in Brea...
乳腺癌(Breast cancer)(下) 5 治疗 5.1 方法注意事项 手术被认为是早期乳腺癌的主要治疗方法;许多患者通过单纯手术治愈。乳腺癌手术的目的包括完整切除原发肿瘤、切缘阴性以降低局部复发的风险、肿瘤及腋窝淋巴结(ALNs)病理分期以提供必要的预后信息。乳腺癌辅助治疗用于治疗微转移病灶(如逃出乳腺和区域淋巴结但还没...
9. Chen Z, et al. Is HER2 ultra‑low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Res Treat. 2023 Nov;202(2):313-323. 10. National Comprehensive Cance...
9.Chen Z, et al. Is HER2 ultra‑low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Res Treat. 2023 Nov;202(2):313-323. 10.National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines...
[2] ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May 2023. Ann Oncol 2021;32(12): 1475-1495 [3] ASCO 2024. Abstract # LBA1001. [4] 中国抗癌协会国际医疗与交流分会, 等. 中华肿瘤杂志,2022,44(12):1288-...
Updated: Jun 17, 2024 Author: Erin V Newton, MD; Chief Editor: Marie Catherine Lee, MD, FACS more...Practice Essentials Early detection remains the primary way to prevent the development of life-threatening breast cancer. Breast cancers that are detected when smaller or nonpalpable are more...
2024 v1美国国立综合癌症网络(NCCN)乳腺癌临床实践指南将SG作为TNBC的二线治疗全人群的1类优选推荐,T-DXd推荐用于不伴胚系BRCA1/2的HER2低表达人群治疗[7]。2023年《ESMO HER2低表达乳腺癌定义、诊断和管理共识》指出,对于HER2低表达晚期TNBC...